WEKO3
アイテム
{"_buckets": {"deposit": "d9891f07-768e-4d58-9046-b11335784e7f"}, "_deposit": {"created_by": 2, "id": "11538", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "11538"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00011538", "sets": ["30"]}, "author_link": ["44192", "44195", "44185", "44196", "44188", "44194", "44189", "44193", "44197", "44190", "44186", "44191", "44187"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "213", "bibliographicPageStart": "209", "bibliographicVolumeNumber": "95", "bibliographic_titles": [{"bibliographic_title": "International Journal of Hematology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "International Journal of Hematology, 95(2), pp.209-213; 2012", "subitem_description_type": "Other"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s12185-012-1005-1", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© The Japanese Society of Hematology 2012"}, {"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10797094", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "09255710", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "18653774", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Itonaga, Hidehiro"}], "nameIdentifiers": [{"nameIdentifier": "44185", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsushima, Hideki"}], "nameIdentifiers": [{"nameIdentifier": "44186", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hata, Tomoko"}], "nameIdentifiers": [{"nameIdentifier": "44187", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuo, Emi"}], "nameIdentifiers": [{"nameIdentifier": "44188", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imanishi, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "44189", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imaizumi, Yoshitaka"}], "nameIdentifiers": [{"nameIdentifier": "44190", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kawaguchi, Yasuhisa"}], "nameIdentifiers": [{"nameIdentifier": "44191", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fukushima, Takuya"}], "nameIdentifiers": [{"nameIdentifier": "44192", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Doi, Yuko"}], "nameIdentifiers": [{"nameIdentifier": "44193", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mori, Sayaka"}], "nameIdentifiers": [{"nameIdentifier": "44194", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamihira, Shimeru"}], "nameIdentifiers": [{"nameIdentifier": "44195", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomonaga, Masao"}], "nameIdentifiers": [{"nameIdentifier": "44196", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "44197", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "IJH95_209.pdf", "filesize": [{"value": "413.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 413700.0, "url": {"label": "IJH95_209.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/11538/files/IJH95_209.pdf"}, "version_id": "e7d69f65-7b03-404e-9547-25ff9e869dc9"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Chronic myelogenous leukemia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Imatinib", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Interferon", "subitem_subject_scheme": "Other"}, {"subitem_subject": "T315I", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/27907", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-03-01"}, "publish_date": "2013-03-01", "publish_status": "0", "recid": "11538", "relation": {}, "relation_version_is_last": true, "title": ["Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa"], "weko_shared_id": -1}
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa
http://hdl.handle.net/10069/27907
http://hdl.handle.net/10069/27907be4f1db9-9c63-47e0-8785-f4e16a3be999
名前 / ファイル | ライセンス | アクション |
---|---|---|
IJH95_209.pdf (413.7 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-03-01 | |||||
タイトル | ||||||
タイトル | Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Chronic myelogenous leukemia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Imatinib | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Interferon | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | T315I | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Itonaga, Hidehiro
× Itonaga, Hidehiro× Tsushima, Hideki× Hata, Tomoko× Matsuo, Emi× Imanishi, Daisuke× Imaizumi, Yoshitaka× Kawaguchi, Yasuhisa× Fukushima, Takuya× Doi, Yuko× Mori, Sayaka× Kamihira, Shimeru× Tomonaga, Masao× Miyazaki, Yasushi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The T315I BCR-ABL mutation in chronic myelogenous leukemia (CML) patients is responsible for up to 20% of all clinically observed resistance. This mutation confers resistance not only to imatinib, but also to second-generation BCR-ABL tyrosine kinases, such as nilotinib and dasatinib. A number of strategies have been implemented to overcome this resistance, but allogeneic stem cell transplantation remains the only established therapeutic option for a cure. A 61-year-old male was diagnosed with Philadelphia chromosome-positive chronic-phase CML in 2002. He was initially treated with imatinib and complete cytogenetic response (CCyR) was achieved 12 months later. However, after 18 months, a loss of CCyR was observed and a molecular study at 24 months revealed a T315I mutation of the BCR-ABL gene. At 30 months, imatinib/interferon-alfa (IFNα) combination therapy was initiated in an effort to overcome the resistance. Thirty months later, he re-achieved CCyR, and the T315I BCR-ABL mutation disappeared at 51 months. To our knowledge, this is the first case report showing the effectiveness of imatinib/IFNα combination therapy for CML patients bearing the T315I BCR-ABL mutation. | |||||
書誌情報 |
International Journal of Hematology 巻 95, 号 2, p. 209-213, 発行日 2012-02 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 09255710 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 18653774 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA10797094 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s12185-012-1005-1 | |||||
権利 | ||||||
権利情報 | © The Japanese Society of Hematology 2012 | |||||
権利 | ||||||
権利情報 | The original publication is available at www.springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | International Journal of Hematology, 95(2), pp.209-213; 2012 |